information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Monday, 23 June 2014

What have happened to Biocontrol Limited company and to product Biophage-PA?

 I have written this post many years ago .

" Concrete Evidence for Phage Therapy
Wednesday, 25 November 2009
From:

"A controlled clinical trial of a therapeutic
bacteriophage
preparation in chronic otitis
due to antibiotic-resistant
Pseudomonas aeruginosa;a preliminary report of efficacy"

UCL Ear Institute and Royal National Throat, Nose and Ear Hospital, Grays Inn Road, London, and Biocontrol Limited, BioCity, Pennyfoot Street, Nottingham, UK Clin. Otolaryngol. 2009, 34, 349–357

The present controlled trial of bacteriophages indicates that this form of biological therapy has considerable promise.


Digital photography before (a) and after (b) in patient A0012.
Patient A0012 had a longstanding resistant otitis externa. There was swelling of the deep canal skin and ulceration in the roof of the canal adjacent to the tympanic membrane. By day 42 this had resolved and the patient was essentially symptom free"




What have happened to phage product Biophage-PA for the treatment of chronic inner ear infections and  to phage product BioPhage-PR for the treatment of lung infections in cystic fibrosis patients?  


BioVet-PA and BioPhage-PA from Biocontrol Limited






The first step is to collect the information about  Biocontrol Limited  company ( the link in the old post  is not active).

 By this document emerges that the main products were phages for Pseudomonas aeruginosa with a potential use in different clinical situations. Biocontrol Limited company   is
now a subsidary of AmpliPhi Biosciences Corporation.



 Link

 




 The treatment of chronic inner ear infections by phages in theory is more easy respect the treatment of lung infections in cystic fibrosis patients because the infection of the inner ear is an infection ouside the body and  for that reason is the best situation for a  lytic action  by phages. 


Why after 5 years (2009-2014) there are not others  clinical evaluations on the field for this Phage cocktail (six phages) regarding the treatment of chronic inner ear infections ?
The inner ear is accessible to phages and this anatomical position is  good  because the obstacle presence to the action  of  phages is limited. Are there some reasons? One reason could be the biofilm presence  that does not allow the action of phage cocktail.

From this web site there is the confirmation :



My  objections:
Is necessary to render the biofilm pemeable to Phages before to start in the treatment of chronic inner ear infections by phage cocktail  ?
Is a broad-spectrum phage cocktail  impossible to prepare for this clinical patology   because it is necessary to customize the cocktail for each patient  like the document described above?